Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:146
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 28 条
  • [1] AZATHIOPRINE IN THE TREATMENT OF PEMPHIGUS VULGARIS - A LONG-TERM FOLLOW-UP
    ABERER, W
    WOLFFSCHREINER, EC
    STINGL, G
    WOLFF, K
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1987, 16 (03) : 527 - 533
  • [2] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [3] The role of IVIg treatment in severe pemphigus vulgaris
    Baum, S
    Scope, A
    Barzilai, A
    Azizi, E
    Trau, H
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (05) : 548 - 552
  • [4] A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus
    Beissert, Stefan
    Werfel, Thomas
    Frieling, Uta
    Boehm, Markus
    Sticherling, Michael
    Stadler, Rudolf
    Zillikens, Detlev
    Rzany, Berthold
    Hunzelmann, Nicolas
    Meurer, Michael
    Gollnick, Harald
    Ruzicka, Thomas
    Pillekamp, Hans
    Junghans, Volker
    Luger, Thomas A.
    [J]. ARCHIVES OF DERMATOLOGY, 2006, 142 (11) : 1447 - 1454
  • [5] IVIg treatment of pemphigus: How it works & how to use it
    Bystryn, JC
    Rudolph, JL
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) : 1093 - 1098
  • [6] Treatment of pemphigus with intravenous immunoglobulin
    Bystryn, JC
    Jiao, D
    Natow, S
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) : 358 - 363
  • [7] The adjuvant therapy of pemphigus - An update
    Bystryn, JC
    Steinman, NM
    [J]. ARCHIVES OF DERMATOLOGY, 1996, 132 (02) : 203 - 212
  • [8] Influence of treatment on the clinical course of pemphigus vulgaris
    Carson, PJ
    Hameed, A
    Ahmed, AR
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (04) : 645 - 652
  • [9] Chams-Davatchi C, 2002, ANN DERMATOL VENER, V129, P23
  • [10] Chrysomallis Fotis, 1994, International Journal of Dermatology, V33, P803, DOI 10.1111/j.1365-4362.1994.tb01003.x